Literature DB >> 19353483

[Pharmacokinetic MRI of the prostate: parameters for differentiating low-grade and high-grade prostate cancer].

T Franiel1, L Lüdemann, M Taupitz, J Rost, P Asbach, D Beyersdorff.   

Abstract

PURPOSE: To investigate whether pharmacokinetic MRI parameters "perfusion, blood volume, mean transit time (MTT), interstitial volume, permeability, extraction coefficient, delay, and dispersion" allow the differentiation of low-grade (Gleason score < or = 6) and high-grade (Gleason score > or = 7) prostate cancer. MATERIALS AND
METHOD: Forty-two patients with prostate cancer verified by biopsy (PSA 2.7 to 31.4 ng/ml) and scheduled for prostatectomy underwent MRI at 1.5 Tesla using the dynamic contrast-enhanced inversion-prepared dual-contrast gradient echo sequence (temporal resolution, 1.65 s) and a combined endorectal body phased array coil. Parametric maps were computed using a sequential 3-compartment model and the corresponding post-processing algorithms. A total of 41 areas of prostate cancer (15 low-grade, 26 high-grade cancers) in 32 patients were able to be correlated with the prostatectomy specimens and were included in the analysis.
RESULTS: Low-grade prostate cancers had a higher mean blood volume (1.76 % vs. 1.64 %, p = 0.039), longer MTT (6.39 s vs. 3.25 s, p < 0.001), and lower mean permeability (2.57 min (-1) vs. 3.86 min (-1), p = 0.011) than high-grade cancers. No statistically significant difference was found for perfusion (p = 0.069), interstitial volume (p = 0.849), extraction coefficient (p = 0.615), delay (p = 0.489), and dispersion (p = 0.306).
CONCLUSIONS: Blood volume, MTT, and permeability allow the differentiation of low-grade and high-grade prostate cancer. They may be used to detect cancer progression by MRI in patients managed by active surveillance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19353483     DOI: 10.1055/s-0028-1109168

Source DB:  PubMed          Journal:  Rofo        ISSN: 1438-9010


  6 in total

Review 1.  Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer.

Authors:  Tobias Franiel; Bernd Hamm; Hedvig Hricak
Journal:  Eur Radiol       Date:  2010-12-24       Impact factor: 5.315

Review 2.  MRI for men undergoing active surveillance or with rising PSA and negative biopsies.

Authors:  Orit Raz; Masoom Haider; John Trachtenberg; Dan Leibovici; Nathan Lawrentschuk
Journal:  Nat Rev Urol       Date:  2010-10       Impact factor: 14.432

3.  [Prostate cancer].

Authors:  T Franiel; N Eckardt; M Waginger; M Horstmann
Journal:  Radiologe       Date:  2014-05       Impact factor: 0.635

4.  Mutation status of somatic EGFR and KRAS genes in Chinese patients with prostate cancer (PCa).

Authors:  Meng Fu; Wei Zhang; Ling Shan; Jian Song; Donghao Shang; Jianming Ying; Jimao Zhao
Journal:  Virchows Arch       Date:  2014-03-05       Impact factor: 4.064

5.  Active surveillance for favorable-risk prostate cancer: a short review.

Authors:  Nathan Lawrentschuk; Laurence Klotz
Journal:  Korean J Urol       Date:  2010-10-21

6.  Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer.

Authors:  Caterina Peraldo-Neia; Giorgia Migliardi; Maurizia Mello-Grand; Filippo Montemurro; Raffaella Segir; Ymera Pignochino; Giuliana Cavalloni; Bruno Torchio; Luciano Mosso; Giovanna Chiorino; Massimo Aglietta
Journal:  BMC Cancer       Date:  2011-01-25       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.